Tracer library / [211At]At-astatobenzoate

[211At]At-astatobenzoate

Also written as [At-211]astatobenzoate

Radionuclide: At-211 t½ 431 min
Modality: Therapy
Production route: —
Stage: Clinical research
Syntheses indexed: 2

Preclinical only, no clinical indication yet

What it is

Compound class: astatobenzoate/astatobenzamide (para-astatobenzoic acid derivative)
Target / mechanism: —
Clinical application: Brain tumor patients treated with astatinated antitenascin antibody 81C6 injected into tumor resection cavities PMID 11585865
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	HPLC	74	—	Para-Tri-n-Butylstannylbenzamidyl-dPEG4-Carb…Para-Tri-n-Butylstannylbenzamidyl-dPEG4-Carboxylic Acid Methyl Ester, 9	36142567 2022 Int J Mol Sci To a solution containing 100 μg 9 in 100 μL of a 0.05 N HCl MeOH/H2O and 200 μL of a [211At]NaAt solution, pH = 7, ~85 MBq (2.3 mCi), was added 20 μL of a 1 mg/mL aqueous solution of ChT. - a 74% radiochemical yield of [211At]13 by radio-HPLC analysis
—	—	—	70-75%	—	trialkylstannyl precursor	9234271 1994 Nucl Med Biol

Need this precursor?We can point you to suppliers for [211At]At-astatobenzoate, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 9 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 36142567: 'Para-Tri-n-Butylstannylbenzamidyl-dPEG4-Carboxylic Acid Methyl Ester, 9'. Stage set/updated at stage 39 from PMID 11585865: 'have permitted the initiation of a phase I trial of (211)At-labeled chimeric 81C6 administered directly into the tumor resection cavities of brain tumor patients'.